Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Meeting with Analyst/Institutional Investor29-10-2021
29-10-2021
Syngene sees medium-term growth prospects intact despite some margin pressure
Key client markets in the US and Europe that are in process of returning to normal operations are helping the company's discovery services segment26-10-2021
Buy Syngene International; target of Rs 710: ICICI Direct
ICICI Direct is bullish on Syngene International has recommended buy rating on the stock with a target price of Rs 710 in its research report dated October 22, 2021.22-10-2021
Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated October 20, 2021, regarding outcome of the Board Meeting and financials for the quarter and half year ended September 30, 2021, please find enclosed herewith the copy of newspaper publication of the financials in Financial Express (All India Edition) and Vijayavani (Bengaluru Edition) on October 22, 2021.22-10-2021
Earnings Call for Q2FY22 of Syngene International
Conference Call with Syngene International Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.21-10-2021
Q2FY22 Quarterly Result Announced for Syngene International Ltd.
Highlights: Revenue from operations up 17% to Rs. 6,102 Mn PAT increased 9% to Rs. 920 Mn The Company reported quarterly revenue from operations growth of 17% year-on-year to Rs. 6,102 Mn; profit after tax for the quarter, before the exceptional item, increased by 9% year-on-year to Rs. 920 Mn. During the quarter, the Company has taken an exceptional downward adjustment of Rs. 253 million (net of tax) on account of the Government’s recent decision in the quarter to cap the Services Export Incentive Scheme (SEIS) for research and development services at Rs. 50 million for the Financial Year 2020. From the financial year 2016 to 2019 the Company benefited from the SEIS incentive at a rate of 5% on net foreign exchange earned. Following this precedence, the Company assumed a similar SEIS incentive would be available in Financial Year 2020 and included this in the financial results for that year. With capping of incentives at Rs 50 million, the Company has reversed the differential SEIS claim receivables. This has been presented under exceptional items in the financial results for the quarter and half year ended 30 September 2021. In the absence of notification of continuation of SEIS, the company has not accrued any such incentives from FY21 onwards. Hence, the SEIS incentive reversal during the quarter for FY2020 is not indicative of the underlying performance of the business. Commenting on the results, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited, said, "The second quarter was characterized by positive performances in all divisions. In Discovery Services, we saw excellent client demand, particularly within the emerging biopharma segment, as well as further expansion of our relationships with existing clients and our long-term partners in the dedicated research centers During the quarter, we continued to manufacture remdesivir for COVID-19, under a voluntary licensing agreement from Gilead. The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across our operations. These investments play an important role in enhancing productivity, reducing the impact of human error and improving quality systems across our business. We are pleased to have delivered a strong performance in the first half of the year. Careful management of costs, coupled with a robust business continuity plan, enabled us to continue to build capability and capacity to meet the growing requirements of our clients. Notwithstanding the continuing uncertainty of the pandemic, we believe that we are wellpositioned to deliver our guidance of mid-teens revenue growth for the full year.” Result PDF21-10-2021
Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.20-10-2021
Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Press Release in respect of results for the quarter and half year ended September 30, 2021. With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled 'Syngene reports second quarter results-Revenue from operations up 17% to Rs. 6,102 Mn, PAT increased 9% to Rs. 920 Mn'20-10-2021
Syngene International Ltd - 539268 - Board Meeting Outcome for Outcome Of The Board Meeting
Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we wish to inform you that the Board of Directors at its meeting held today, has considered and approved the following: Financial Results: Un-audited financial results (consolidated and standalone) as per Indian Accounting Standards (Ind-AS) for the quarter and half year ended September 30, 2021. A copy of the unaudited financial results along with the Limited Review Reports is enclosed herewith. The above information will also be available on the website of the Company at www.syngeneintl.com. The Board Meeting commenced at 17:30 and concluded at 20:56.20-10-2021
Syngene International Ltd - 539268 - Sub: Outcome Of The Board Meeting
Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we wish to inform you that the Board of Directors at its meeting held today, has considered and approved the following:20-10-2021